Comparison of Standard (7–14 Days) versus Extended (>14 Days) Intravenous Antibiotic Treatment for Vesicoureteral Reflux-Associated Acute Pyelonephritis in Children: A Retrospective Cohort Study
This retrospective cohort study of 99 children with vesicoureteral reflux-associated acute pyelonephritis found that extending intravenous antibiotic treatment beyond 14 days provided no significant benefit over the standard 7–14 day regimen in reducing recurrence rates, total infection episodes, or adverse outcomes.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every year, millions of children develop a serious bacterial infection of the kidneys known as acute pyelonephritis. This condition causes high fevers, pain, and significant distress, and if left unchecked, it can lead to permanent scarring of the kidney tissue. In many young patients, this infection is triggered by a structural flaw called vesicoureteral reflux. In a healthy urinary system, urine flows only one way: from the kidneys down to the bladder and out of the body. In children with this condition, the valve that should stop the flow is weak, allowing urine to leak backward up toward the kidneys. This backflow creates a highway for bacteria to travel from the bladder into the delicate kidney tissue, making infections more likely to return and more difficult to clear.
When doctors treat these infections, they rely on intravenous antibiotics delivered directly into the bloodstream to kill the bacteria. The standard medical practice for most children has long been to administer these drugs for a period of one to two weeks. However, for children with the structural flaw of vesicoureteral reflux, the situation feels more precarious. Because their anatomy allows bacteria to return easily, many clinicians worry that a standard course of treatment might not be long enough to fully eradicate the infection. Consequently, it has become common practice to extend the antibiotic therapy for these specific children, sometimes keeping them on the drugs for more than two weeks. The logic is straightforward: if the infection is harder to clear due to the anatomy, then a longer treatment should provide better protection against recurrence. Yet, until recently, no one had rigorously tested whether this extra time actually makes a difference in preventing the infection from coming back.
Researchers at the Children's Hospital of Chongqing Medical University set out to answer this question by looking back at the medical records of children who had been treated for this specific combination of conditions. They gathered data on 99 children, all diagnosed with acute pyelonephritis caused by vesicoureteral reflux. The team divided these children into two groups based on how long they had received intravenous antibiotics. One group received the standard treatment, lasting between seven and fourteen days. The other group received an extended course, where the antibiotics continued for more than fourteen days. The researchers then followed these children for two years after they left the hospital, carefully tracking whether the infection returned, how many times it happened, and whether the children suffered any severe side effects or changes in their kidney function.
The results of this investigation were clear and somewhat surprising to those who believed longer treatment was necessary. When the researchers compared the two groups, they found no advantage to extending the therapy. At six months after treatment, the rate of infection returning was nearly identical in both groups, with about 38 percent of the standard-treatment children and 33 percent of the extended-treatment children experiencing a recurrence. By the two-year mark, the numbers remained similar, with roughly 44 percent of the standard group and 41 percent of the extended group seeing the infection return. The difference between these percentages was so small that it could easily be attributed to chance rather than the length of the treatment. Furthermore, the total number of kidney infection episodes over the two years was comparable, and neither group showed any signs of improved kidney function or reduced risk of severe adverse events.
The study also examined other factors that might influence whether a child's infection would return. The researchers found that the severity of the initial infection, measured by high white blood cell counts at the time of admission, was linked to a higher risk of the disease coming back. However, the duration of the antibiotic treatment itself was not a deciding factor. Whether a child received a standard course or an extended one did not change their likelihood of a recurrence. The data suggested that once the infection was cleared and the child met specific clinical criteria for stopping the medication, adding more days of antibiotics did not provide any extra shield against the bacteria returning.
This finding challenges the common clinical habit of automatically prolonging treatment for children with this structural abnormality. The researchers noted that their study population was quite young, with a median age of just four months, and many had high-grade reflux, representing a group that is typically considered very high risk. Despite this, the standard regimen proved sufficient. The study did not find that shorter treatment led to more kidney damage or more frequent infections. In fact, the extended treatment offered no measurable benefit in terms of safety or long-term health outcomes. The authors concluded that for the vast majority of children with this condition, the standard seven-to-fourteen-day course is enough to achieve the best possible results.
While the study was limited by its retrospective nature and the fact that it was conducted at a single center, the consistency of the data across a two-year follow-up period provides a strong signal. The researchers emphasized that their findings do not mean that treatment should be rushed or that monitoring is unnecessary. They noted that doctors still need to watch for signs that the infection has not fully cleared, such as persistent fever or abnormal lab results, before stopping medication. However, the practice of routinely extending therapy simply because a child has vesicoureteral reflux appears to be unnecessary. By sticking to the standard duration, medical teams can avoid exposing children to extra doses of medication, reduce the time spent in the hospital, and lower the risk of side effects, all without compromising the child's recovery or future kidney health. The study suggests that for these young patients, the standard approach is not just adequate, but likely the most prudent path forward.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.